Equities research analysts predict that Xenon Pharmaceuticals Inc (NASDAQ:XENE) will post ($0.11) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Xenon Pharmaceuticals’ earnings, with the highest EPS estimate coming in at $0.22 and the lowest estimate coming in at ($0.44). Xenon Pharmaceuticals reported earnings per share of ($0.32) in the same quarter last year, which indicates a positive year over year growth rate of 65.6%. The company is expected to issue its next earnings report on Wednesday, March 14th.
On average, analysts expect that Xenon Pharmaceuticals will report full-year earnings of ($1.49) per share for the current financial year, with EPS estimates ranging from ($1.75) to ($1.01). For the next financial year, analysts anticipate that the firm will post earnings of ($1.67) per share, with EPS estimates ranging from ($2.00) to ($1.07). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Xenon Pharmaceuticals.
Several research firms recently issued reports on XENE. ValuEngine raised shares of Xenon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd. Zacks Investment Research raised shares of Xenon Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, January 21st.
Xenon Pharmaceuticals (NASDAQ XENE) traded down $0.03 on Tuesday, reaching $3.60. 32,900 shares of the company traded hands, compared to its average volume of 53,591. The firm has a market capitalization of $64.79, a PE ratio of -2.26 and a beta of 1.46. Xenon Pharmaceuticals has a 1 year low of $2.10 and a 1 year high of $9.95.
A number of institutional investors and hedge funds have recently bought and sold shares of XENE. Sabby Management LLC raised its holdings in shares of Xenon Pharmaceuticals by 7.1% during the fourth quarter. Sabby Management LLC now owns 329,400 shares of the biopharmaceutical company’s stock worth $931,000 after purchasing an additional 21,800 shares during the period. Renaissance Technologies LLC raised its holdings in shares of Xenon Pharmaceuticals by 59.2% during the fourth quarter. Renaissance Technologies LLC now owns 249,000 shares of the biopharmaceutical company’s stock worth $703,000 after purchasing an additional 92,600 shares during the period. Finally, K2 Principal Fund L.P. raised its holdings in shares of Xenon Pharmaceuticals by 33.5% during the fourth quarter. K2 Principal Fund L.P. now owns 219,543 shares of the biopharmaceutical company’s stock worth $620,000 after purchasing an additional 55,033 shares during the period. 54.48% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: “-$0.11 EPS Expected for Xenon Pharmaceuticals Inc (XENE) This Quarter” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/02/20/0-11-eps-expected-for-xenon-pharmaceuticals-inc-xene-this-quarter.html.
Xenon Pharmaceuticals Company Profile
Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD).
Get a free copy of the Zacks research report on Xenon Pharmaceuticals (XENE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.